Savara Inc Sublease Income
Savara Inc (SVRA) reported Sublease Income of $226.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2020-11-05
- Savara Inc sublease income for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Savara Inc sublease income for the quarter ending 2020-06-30 was $90.00K, a 41.18% decline year-over-year.
- Savara Inc sublease income for the quarter ending 2020-03-31 was $136.00K, a 11.11% decline year-over-year.
- Savara Inc sublease income for the quarter ending 2019-09-30 was $153.00K.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month |
|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $90.00K derived: sum of 2 quarters · filed 2020-11-05 | $226.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $90.00K 10-Q · filed 2020-08-06 | $226.00K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $136.00K 10-Q · filed 2020-05-07 | ||
| 2019-09-30 | $153.00K 10-Q · filed 2019-11-07 | $306.00K derived: sum of 2 quarters · filed 2019-11-07 | $461.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $153.00K 10-Q · filed 2019-08-08 | $304.00K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $153.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |